eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2018
vol. 35
 
Share:
Send email
Share:
abstract:
Original paper

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma

Krzysztof Pałgan
,
Magdalena Żbikowska-Götz
,
Kinga Lis
,
Elżbieta Chrzaniecka
,
Zbigniew Bartuzi

Adv Dermatol Allergol 2018; XXXV (5): 495-497
DOI: https://doi.org/10.5114/ada.2018.77241
Online publish date: 2018/07/19
View full text Get citation
 
Introduction
Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

Aim
To analyse forced expiratory volume in 1 s (FEV1) following the adminstration of omalizumab.

Material and methods
Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

Results
Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.

Conclusions
These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.

keywords:

asthma, omalizumab, spirometry, forced expiratory volume in 1 s
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.